Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Epidemiological Study to Determine the Prevalence of ctDNA Positivity in Participants With Stage II (High Risk) or Stage III CRC After Surgery With Curative (R0) Intent and Subsequent Adjuvant Chemotherapy With Monitoring of ctDNA During Clinical Follow-up

NCT04813627 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT04813627
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04813627 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Epidemiological Study to Determine the Prevalence of ctDNA Positivity in Participants With Stage II (High Risk) or Stage III CRC After Surgery With Curative (R0) Intent and Subsequent Adjuvant Chemotherapy With Monitoring of ctDNA During Clinical Follow-up
Lead sponsor
BioNTech SE
Phase
Observational
Overall status
Completed
Start date
July 2, 2021
Completion date
April 23, 2026
Enrollment
2,079 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer stage ii, colorectal cancer stage iii